2025
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome
Garcia-Manero G, Gaddh M, Platzbecker U, Lindsley R, Larson S, Chevassut T, Fenaux P, Komrokji R, Lyons R, Al-Kali A, Jiang Y, Bothos J, Townsley D, Zeidan A. A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome. Annals Of Hematology 2025, 104: 1577-1585. PMID: 40153010, PMCID: PMC12031784, DOI: 10.1007/s00277-024-06081-4.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsDose-limiting toxicityPhase 1 studyPD-L1Adverse eventsUpregulation of programmed death ligand 1Marrow complete responseDeath-ligand 1Hypomethylating agent treatmentPrimary safety endpointProgression to AMLEvaluation of clinical outcomesComplete responseHematologic improvementIWG criteriaMyelodysplastic syndromeOpen-labelSecondary endpointsSafety endpointsClinical outcomesLimited efficacyPatientsLigand 1Agent treatmentOverall response
2016
Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors.
Epstein M, Alvarez P, Reaven N, Funk S, McGaughey K, Brenner M, Benton W, Golestaneh L. Evaluation of clinical outcomes and costs based on prescribed dose level of renin-angiotensin-aldosterone system inhibitors. The American Journal Of Managed Care 2016, 22: s311-s324. PMID: 27668789.Peer-Reviewed Original ResearchRenin-angiotensin-aldosterone system inhibitorsPrescribed dose levelsEvaluation of clinical outcomesClinical outcomesSystem inhibitors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply